Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P82664

UPID:
RT10_HUMAN

ALTERNATIVE NAMES:
28S ribosomal protein S10, mitochondrial

ALTERNATIVE UPACC:
P82664; B2RE89; Q9H3E5; Q9NVR3

BACKGROUND:
Small ribosomal subunit protein uS10m, alternatively named 28S ribosomal protein S10, mitochondrial, is integral to mitochondrial protein synthesis. This protein is a component of the mitochondrial ribosome, where it participates in translating the genetic code into functional proteins. Given its essential role in mitochondrial operations, uS10m is fundamental for cellular energy production and overall mitochondrial health.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Small ribosomal subunit protein uS10m could open doors to potential therapeutic strategies. By elucidating its function in mitochondrial protein synthesis, researchers can explore targeted interventions for conditions stemming from mitochondrial impairments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.